Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients : a 9-year cohort study in Senegal
© 2010 Blackwell Publishing Ltd..
OBJECTIVE: The use of didanosine (ddI) in first-line antiretroviral therapy has been recently promoted for resource-limited settings. We therefore compared the long-term effectiveness and safety of the regimen combining ddI, lamivudine, and efavirenz or nevirapine with that of the WHO-recommended regimen of zidovudine (ZDV), lamivudine, and efavirenz or nevirapine in antiretroviral-naïve patients in Senegal.
METHODS: Observational cohort study of patients enrolled between January 2000 and April 2002 in the Senegalese antiretroviral drug access initiative. Multivariate analyses were performed to compare, between the ddI and ZDV groups, the proportion of patients with a viral load <500 copies/ml during follow-up; the increase in the CD4 cell count; survival; treatment changes and severe adverse events.
RESULTS: Of 151 patients, 71 received the ddI-based treatment and 80 received the ZDV-based treatment. Throughout follow-up, 80-95% of patients had a viral load below 500 copies/ml in both the ddI and ZDV groups (P = 0.5). The CD4 cell count increased after treatment initiation from 176 to 497 cells/mm(3) in the ddI group and from 176 to 567 cells/mm(3) in the ZDV group (P > 0.3). The rate of death tended to be higher in the ddI group (P = 0.06). ddI was less commonly discontinued than ZDV (P = 0.03).
CONCLUSION: The combination of ddI, lamivudine, and efavirenz or nevirapine resulted in sustained viral suppression and immunological recovery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Tropical medicine & international health : TM & IH - 16(2011), 2 vom: 01. Feb., Seite 217-22 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laurent, Christian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.04.2011 Date Revised 09.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/j.1365-3156.2010.02690.x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM20371637X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM20371637X | ||
| 003 | DE-627 | ||
| 005 | 20231223230642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-3156.2010.02690.x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0679.xml |
| 035 | |a (DE-627)NLM20371637X | ||
| 035 | |a (NLM)21087377 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laurent, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients |b a 9-year cohort study in Senegal |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2011 | ||
| 500 | |a Date Revised 09.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2010 Blackwell Publishing Ltd. | ||
| 520 | |a OBJECTIVE: The use of didanosine (ddI) in first-line antiretroviral therapy has been recently promoted for resource-limited settings. We therefore compared the long-term effectiveness and safety of the regimen combining ddI, lamivudine, and efavirenz or nevirapine with that of the WHO-recommended regimen of zidovudine (ZDV), lamivudine, and efavirenz or nevirapine in antiretroviral-naïve patients in Senegal | ||
| 520 | |a METHODS: Observational cohort study of patients enrolled between January 2000 and April 2002 in the Senegalese antiretroviral drug access initiative. Multivariate analyses were performed to compare, between the ddI and ZDV groups, the proportion of patients with a viral load <500 copies/ml during follow-up; the increase in the CD4 cell count; survival; treatment changes and severe adverse events | ||
| 520 | |a RESULTS: Of 151 patients, 71 received the ddI-based treatment and 80 received the ZDV-based treatment. Throughout follow-up, 80-95% of patients had a viral load below 500 copies/ml in both the ddI and ZDV groups (P = 0.5). The CD4 cell count increased after treatment initiation from 176 to 497 cells/mm(3) in the ddI group and from 176 to 567 cells/mm(3) in the ZDV group (P > 0.3). The rate of death tended to be higher in the ddI group (P = 0.06). ddI was less commonly discontinued than ZDV (P = 0.03) | ||
| 520 | |a CONCLUSION: The combination of ddI, lamivudine, and efavirenz or nevirapine resulted in sustained viral suppression and immunological recovery | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Controlled Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Alkynes |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Benzoxazines |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a Zidovudine |2 NLM | |
| 650 | 7 | |a 4B9XT59T7S |2 NLM | |
| 650 | 7 | |a Nevirapine |2 NLM | |
| 650 | 7 | |a 99DK7FVK1H |2 NLM | |
| 650 | 7 | |a efavirenz |2 NLM | |
| 650 | 7 | |a JE6H2O27P8 |2 NLM | |
| 650 | 7 | |a Didanosine |2 NLM | |
| 650 | 7 | |a K3GDH6OH08 |2 NLM | |
| 700 | 1 | |a Tchatchueng Mbougua, Jules Brice |e verfasserin |4 aut | |
| 700 | 1 | |a Ngom Guèye, Ndèye Fatou |e verfasserin |4 aut | |
| 700 | 1 | |a Etard, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Diouf, Assane |e verfasserin |4 aut | |
| 700 | 1 | |a Landman, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Molinari, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Girard, Pierre-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Sow, Papa Salif |e verfasserin |4 aut | |
| 700 | 1 | |a Ndoye, Ibra |e verfasserin |4 aut | |
| 700 | 1 | |a Delaporte, Eric |e verfasserin |4 aut | |
| 700 | 0 | |a ANRS 1215/1290 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Ndoye, I |e investigator |4 oth | |
| 700 | 1 | |a de Beaudrap, P |e investigator |4 oth | |
| 700 | 1 | |a Delaporte, E |e investigator |4 oth | |
| 700 | 1 | |a Etard, J F |e investigator |4 oth | |
| 700 | 1 | |a Laurent, C |e investigator |4 oth | |
| 700 | 1 | |a Taverne, B |e investigator |4 oth | |
| 700 | 1 | |a Bitèye, M M |e investigator |4 oth | |
| 700 | 1 | |a Dieng, A B |e investigator |4 oth | |
| 700 | 1 | |a Diouf, A |e investigator |4 oth | |
| 700 | 1 | |a Sarr, A |e investigator |4 oth | |
| 700 | 1 | |a Zié, L |e investigator |4 oth | |
| 700 | 1 | |a Cilote, V |e investigator |4 oth | |
| 700 | 1 | |a Lanièce, I |e investigator |4 oth | |
| 700 | 1 | |a Ndiaye, I |e investigator |4 oth | |
| 700 | 1 | |a Ndir, A |e investigator |4 oth | |
| 700 | 1 | |a Ndour, C T |e investigator |4 oth | |
| 700 | 1 | |a Senghor, C S |e investigator |4 oth | |
| 700 | 1 | |a Sow, P S |e investigator |4 oth | |
| 700 | 1 | |a Basty Fall, M |e investigator |4 oth | |
| 700 | 1 | |a Dia Badiane, N M |e investigator |4 oth | |
| 700 | 1 | |a Diakhaté, N |e investigator |4 oth | |
| 700 | 1 | |a Diallo, M |e investigator |4 oth | |
| 700 | 1 | |a Diouf, L M |e investigator |4 oth | |
| 700 | 1 | |a Ngom Guèye, N F |e investigator |4 oth | |
| 700 | 1 | |a Ba Fall, K |e investigator |4 oth | |
| 700 | 1 | |a Guèye, P M |e investigator |4 oth | |
| 700 | 1 | |a Périno, C |e investigator |4 oth | |
| 700 | 1 | |a Diaw, P A |e investigator |4 oth | |
| 700 | 1 | |a Diop Ndiaye, H |e investigator |4 oth | |
| 700 | 1 | |a Mboup, S |e investigator |4 oth | |
| 700 | 1 | |a Touré Kane, N C |e investigator |4 oth | |
| 700 | 1 | |a Sow, K |e investigator |4 oth | |
| 700 | 1 | |a Diop, K |e investigator |4 oth | |
| 700 | 1 | |a Ndiaye, B |e investigator |4 oth | |
| 700 | 1 | |a Ciss, M |e investigator |4 oth | |
| 700 | 1 | |a Desclaux, A |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Tropical medicine & international health : TM & IH |d 1997 |g 16(2011), 2 vom: 01. Feb., Seite 217-22 |w (DE-627)NLM086387235 |x 1365-3156 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2011 |g number:2 |g day:01 |g month:02 |g pages:217-22 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-3156.2010.02690.x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2011 |e 2 |b 01 |c 02 |h 217-22 | ||